{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:31:28Z","timestamp":1773790288996,"version":"3.50.1"},"reference-count":27,"publisher":"Japanese Society of Toxicology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2012]]},"DOI":"10.2131\/jts.37.261","type":"journal-article","created":{"date-parts":[[2012,4,2]],"date-time":"2012-04-02T04:19:31Z","timestamp":1333340371000},"page":"261-267","source":"Crossref","is-referenced-by-count":20,"title":["&lt;i&gt;In vitro&lt;\/i&gt; validation of drug-induced phospholipidosis"],"prefix":"10.2131","volume":"37","author":[{"given":"Sora","family":"Park","sequence":"first","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Jin","family":"Choi","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Alakoskela, J.M., Vitovic, P. and Kinnunen, P.K.J. (2009): Screening for the drug-phospholipid interaction: correlation to phospholipidosis. Chem. Med. Chem.,<b> 4<\/b>, 1224-1251.","DOI":"10.1002\/cmdc.200900052"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Anderson, N. and Borlak, J. (2006): Drug-induced phospholipidosis. FEBS Letters, <b>580<\/b>, 5333-5540.","DOI":"10.1016\/j.febslet.2006.08.061"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024778329320"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.665-675.2000"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Fujimura, H., Dekura, E., Kurabe, M., Shimazu, N., Koitabashi, M. and Toriumi, W. (2007): Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development. Exp. Toxicol. Pathol., <b>58<\/b>, 375-385.","DOI":"10.1016\/j.etp.2007.01.004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Gonzalez-Rhoti, R.J., Zander, D.S. and Ros, P.R. (1995): Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. Chest, <b>107<\/b>, 1763-1765.","DOI":"10.1378\/chest.107.6.1763"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Honegger, U.E., Quack, G. and Wiesmann, U.N. (1993): Evidence for lysosomotropism of memantine in cultured human Cells: Cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission. Biochem. Pharmacol., <b>73<\/b>, 202-208.","DOI":"10.1111\/j.1600-0773.1993.tb01564.x"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/65.2.166"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Kasahara, T., Tomita, K., Murano, H., Harada, T., Tsubakimoto, K., Ogihara, T., Ohnishi, S. and Kakinuma, C. (2006): Establishment of an <i>in vitro<\/i> high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol. Sci., <b>90<\/b>, 133-141.","DOI":"10.1093\/toxsci\/kfj067"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Leeson, G.A., Biedenbach, S.A., Chan, K.Y., Gibson, J.P. and Wright, G.J. (1976): Decrease in the activity of the drug-metabolizing enzymes of rat liver following the administration of tilorone hydrochloride. Drug Metab. Dispos., <b>4<\/b>, 232-238.","DOI":"10.1016\/S0090-9556(25)06009-X"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(78)90435-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Miyamoto, S., Matsumoto, A., Mori, I. and Horinouchi, A. (2009): Relationship between <i>in vitro<\/i> phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats. Toxicol. Mech. Methods, <b>19<\/b>, 477-485.","DOI":"10.1080\/15376510903322834"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2.5.687"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-006-0176-z"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.665-675.2000"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfm157"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1081\/DCT-200039743"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Reasor, M.J. and Kacew, S. (2001): Drug-induced phospholipidosis: Are there functional consequences? Exp. Bio. Med., <b>226<\/b>, 825-830.","DOI":"10.1177\/153537020122600903"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.4.567"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfh264"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-108043"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1021\/tx00047a006"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Tengstrand, E.A., Miwa, G.T. and Hsieh, F.Y. (2010): Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities. Expert Opin. Drug Metab. Toxicol., <b>6<\/b>, 555-570.","DOI":"10.1517\/17425251003601961"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Waters, E., Wang, J.H., Redmond, H.P., Wu, Q.D., Kay, E. and Bouchier-Hayes, D. (2001): Role of taurine in preventing acetaminophen-induced hepatic injury in the rat. Am. J. Physiol. Gastrointest. Liver Physiol., <b>280<\/b>, G1274-1279.","DOI":"10.1152\/ajpgi.2001.280.6.G1274"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Weiss, J.N., Weinberg, R.S. and Regelson, W. (1980): Keratopathy after oral administration of tilorone hydrochloride. Am. J. Ophthalmol., <b>89<\/b>, 46-53.","DOI":"10.1016\/0002-9394(80)90227-5"},{"key":"26","unstructured":"www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/maceuticalScienceandClinicalPharmacology\/UCM207737.pdf : FDA webpage (last visited in Oct 17, 2011)"},{"issue":"5","key":"27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/oxfordjournals.jbchem.a129695","volume":"70","author":"YAMAMOTO Akira","year":"1971","ISSN":"https:\/\/id.crossref.org\/issn\/0021-924X","issn-type":"print"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/37\/2\/37_2_261\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T20:06:57Z","timestamp":1742846817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/37\/2\/37_2_261\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.37.261","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}